Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis

Neuromuscular Disorders

Volumn 11, Issue 5, 2001, Pages 447-451

  Van Der Meulen, Marjon F G ^a   Hoogendijk, Jessica E ^a   Moons, Karl G M ^a   Veldman, Henk ^a   Badrising, Umesh A ^b   Wokke, John H J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnostic test; Inclusion body myositis; Polymyositis; Rimmed vacuoles; SMI 31

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SMI 31; NEUROFILAMENT PHOSPHOPROTEIN ANTIBODDY; NEUROFILAMENT PROTEIN; PHOSPHOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL VACUOLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCLUSION BODY MYOSITIS; MALE; MUSCLE BIOPSY; NEUROFILAMENT; POLYMYOSITIS; PRIORITY JOURNAL;

ADULT; AGED; EOSINE YELLOWISH-(YS); FEMALE; HEMATOXYLIN; HUMANS; INCLUSION BODIES; MALE; MIDDLE AGED; MYOSITIS, INCLUSION BODY; NEUROFILAMENT PROTEINS; PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; STAINING AND LABELING; VACUOLES;

EID: 0034981219     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-8966(00)00219-4     Document Type: Article

References (15)

1. Polymyositis, dermatomyositis and inclusion-body myositis (see comments)
2. Inclusion body myositis and myopathies
3. Inflammatory myopathies: Inclusion body myositis
4. Inclusion body myositis: Clinical and pathological boundaries
5. Inclusion body myositis presenting as treatment-resistant polymyositis
6. Clinically unsuspected inclusion body myositis
7. Absence of characteristic features in two patients with inclusion body myositis
8. Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis (see comments)
9. The meaning and use of the area under a receiver operating characteristic (ROC) curve
10. Rimmed vacuoles
11. Scleroderma-polymyositis overlap syndrome associated with anti-Ku antibody and rimmed vacuole formation
12. Clinical heterogeneity and treatment response in inclusion body myositis
13. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy
14. Guidelines for the assessment of new diagnostic tests